Mount Sinai Launches New Center for Artificial Intelligence – Xtelligent Healthcare Media
– The Icahn School of Medicine at Mount Sinai has announced the launch of a new center that will advance clinical care with artificial intelligence, genomic screening, and data science.
The Hamilton and Amabel James Center for Artificial Intelligence and Human Health in Manhattan will allow researchers to enhance their understanding, diagnosis, and treatment of human diseases.
The new facility will house the Center for Genomic Health, which will accelerate the integration of genomics and routine clinical care throughout Mount Sinai Health System.
“Our goal is to use artificial intelligence to translate vast knowledge from deep databases of genomic information to improve the lives of every patient at Mount Sinai,” said Eimear Kenny, PhD, Founding Director of the Center for Genomic Health and Associate Professor of Medicine, (General Internal Medicine), and Genetics and Genomic Sciences.
The Center for Genomic Health will help researchers and clinicians develop innovative ways to make genetic data a standard part of healthcare.
READ MORE: Finding a Happy Home for Artificial Intelligence in Healthcare
“The new building will bring together a generation of scientists and physicians who are trained in big data and artificial intelligence—tools that can enable the development of precise genomic tests and increasingly sophisticated ways to integrate genomic information into routine patient care,” said Noura Abul-Husn, MD, PhD, Clinical Director of the Center for Genomic Health and Senior Faculty of Medicine, (General Internal Medicine), and Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai.
The new artificial intelligence center will also focus on integrating genomic insights with -omics, such as epigenomics, pharmacogenomics, and exposomics. Researchers will combine this information with data from EHRs and wearable devices to model the molecular, cellular, and circuit networks that facilitate disease progression.
“Novel data-driven predictions will be tightly integrated with high-throughput experiments to validate the therapeutic potential of each prediction,” said Adam Margolin, PhD, Professor and Chair of the Department of Genetics and Genomic Sciences and Senior Associate Dean of Precision Medicine at Mount Sinai.
“Clinical experts in key disease areas will work side-by-side with data scientists to translate the most promising therapies to benefit patients. We have the potential to transform the way care givers deliver cost-effective, high quality health care to their patients, far beyond providing simple diagnoses. Mount Sinai wants to be on the frontlines of discovery.”
The facility will use artificial intelligence to enhance imaging technology as well. Researchers will leverage AI tools to improve the diagnostic power of X-rays, MRIs, CT, and PET scans, speed up disease detection, and help with drug development.
READ MORE: Cleveland Clinic Creates Artificial Intelligence Innovation Center
“We see a huge potential in using algorithms to automate the image interpretation and to acquire images much more quickly at high resolution – so that we can better detect disease and make it less burdensome for the patient,” said Zahi Fayad, PhD, Director of the Translational and Molecular Imaging Institute, and Vice Chair for Research for the Department of Radiology, at Mount Sinai.
“In addition to AI, we envision advance capabilities in two important areas: computer vision and augmented reality, and next generation medical technology enabling development of new medical devices, sensors and robotics.”
The new center is funded by a donation from Hamilton Evans’ Tony’ and Amabel James and is expected to open in late 2021. The new facility will open with approximately 40 principal investigators, and 250 graduate students, postdoctoral fellows, computer scientists, and other support staff.
“Artificial intelligence and machine learning are spurring innovation across many different fields, but perhaps most significantly in healthcare,” said Mr. James, Executive Vice Chairman of Blackstone, a New York-based investment firm.
“Mount Sinai has proven itself a pioneer in data mining to improve patient diagnosis and treatment, and I am pleased to support its mission and accelerate the development of cutting-edge therapies and technologies that have the potential to change lives around the world.”
READ MORE: Education, Culture Key to Artificial Intelligence in Healthcare
The Hamilton and Amabel James Center for Artificial Intelligence and Human Health will add to Mount Sinai’s efforts to leverage innovative technology and accelerate research to improve clinical care.
In 2018, the health system launched the Center for Biomedical Blockchain Research, which explores how to use secure technologies to solve problems in biomedical research and improve clinical decision-making.
Mount Sinai also recently partnered with Sema4 and Sanofi to advance precision medicine treatments for patients with asthma.
“Mount Sinai has consistently been at the forefront of advancing healthcare across medical disciplines and this initiative represents our next step forward in building on that legacy,” said Kenneth L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System.
“We see the potential of artificial intelligence to radically transform the care that patients receive, and we want to shape and lead this effort. We are grateful to Mr. and Mrs. James for their generous gift, which will create a hub where our talented researchers can collaborate in unprecedented ways and bring forward ideas and innovative technologies that achieve better outcomes for our patients.”
With the launch of this new facility, Mount Sinai will further advance the use of artificial intelligence in healthcare.
“We are looking at a future where artificial intelligence has the capacity to completely disrupt healthcare and Mount Sinai is going to be at the forefront of that revolution, driving the conversation, engaging stakeholders worldwide in developing solutions, and making this bold future a reality,” said Dennis S. Charney, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine, and President for Academic Affairs for the Mount Sinai Health System.